摘要
目的观察丹红注射液治疗肺源性心脏病(肺心病)失代偿期的临床疗效。方法将60例肺心病失代偿期患者随机分为治疗组和对照组,各30例,对照组给予常规治疗,治疗组在常规治疗的基础上加用丹红注射液静脉滴注,14d为1个疗程,治疗后比较两组治疗效果。结果治疗组总有效率为97.0%,高于对照组的77.0%,差异有统计学意义(P<0.01)。两组均未出现严重不良反应。治疗组动脉血氧分压(PaO2)上升幅度和动脉血二氧化碳分压(PaCO2)下降幅度均大于对照组,差异有统计学意义(P<0.05)。结论丹红注射液是辅助治疗肺心病失代偿期的有效安全药物,值得临床推广。
Objective To observe the effect of Danhong injection in the treatment of pulmonary heart disease stage of decompensation. Methods 60 patients with decompensated pulmonary heart disease were randomly divided into treatment group and control group, each 30 cases. The control group was given conventional treatment, the treatment group was given conven- tional treatment combined with danhong injection on intravenous drip, 14d for 1 course, treatment effect of two groups was com- pared after the treatment. Results The total effective rate of treatment group was 97.0%, which was higher than the control group of 77.0% the difference was statistically significant （P 〈 0. 01 ）. There was no severe adverse reaction occurred in both groups. The arterial blood oxygen partial pressure （PaO2） rise and arterial blood carbon dioxide partial pressure （PaCO2） de- cline of treatment group were greater than the control group, the difference was statistically significant （P 〈 0. 05）. Conclusion Danhong injection in adjuvant treatment of pulmonary heart disease is decompensated effective safe drugs, which is worthy of promotion.
出处
《实用心脑肺血管病杂志》
2013年第9期50-51,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
丹红注射液
肺心病
治疗结果
Danhong injection
Pulmonary heart disease
Treatment outcome
